Anne Stevens

Anne is the Vice President of Business Development at AbCellera and serves on the Board of Directors of LifeSciences BC and Aequus Pharmaceuticals. Previously, Anne was a Co-Founder and Senior Partner of Northview Lifesciences, an entity which invests in and provides strategic advisory services to a number of life sciences companies. Anne also served as the Chief Operating Officer for Aequus Pharmaceuticals, a publicly listed Canadian specialty pharmaceutical company where she was responsible for developing and executing on the corporate strategy, including building out the commercial pipeline through the execution of various types of partnerships with multi-national organizations. Anne’s earlier experience includes roles of increasing responsibility in business and corporate development, including at Cardiome Pharma Corp. and Bayer HealthCare, where she was responsible for strategic planning and value analysis of internal R&D as well as the commercial success and business development of a portfolio of products within several key therapeutic areas.

Anne holds a Bachelor of Science degree and Master of Health Administration degree from University of British Columbia and is a past winner of Business in Vancouver’s “Top 40 Under 40 Award”.

Carl Hansen

Carl Hansen is AbCellera’s founding CEO. Until August 2019, Carl was a Professor at the University of British Columbia, where he co-authored over 65 manuscripts in the fields of microfluidics, immunology, genomics, and nanotechnology. He is an inventor of over 50 US patents and 63 US patent applications that are represented in 7 commercial products. He received the Michael Smith Career investigator award and was recently named one of the “Top 5 Canadian CEOs who elevate their companies.” Carl received his PhD in Applied Physics/Biotechnology from Caltech, and a BASc in Engineering Physics and Honors Mathematics from the University of British Columbia. Before leading AbCellera, he was a scientific Co-Founder of Precision Nanosystems, a Vancouver-based company developing next-generation delivery technology for genetic medicines, and served on the SAB of Fluidigm Corp.